Compare Crispr Therapeutics AG (CRSP) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Freshworks Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Freshworks Inc trades at $13.92 (market cap $3.56B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Freshworks Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Freshworks Inc for 39 Days on average.
| CRSP | FRSH | |
|---|---|---|
Market Cap | $4.88B | $3.56B |
Volume | 2,861,747 | 9,066,454 |
Sector | Health | Technology |
52-Week High | $74.92 | $13.92 |
52-Week Low | $44.34 | $6.88 |
Typical Hold Time | 77 Days | 39 Days |
Enterprise Value | $3.30B | $2.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Freshworks (FRSH) trades at $13.64, up 0.29% on the day, with a bullish technical signal and strong fundamental momentum. The company achieved its first quarter of GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains robust at 16% year-over-year, supported by a high gross margin of 84.96%. Analyst sentiment is evenly split between Buy and Hold, with a consensus price target of $14.60.
The outlook for FRSH is positive, driven by sustained revenue growth, improving profitability, and strategic focus on AI and enterprise solutions. Key risks include competitive pressures in the SaaS sector and execution challenges in maintaining growth momentum. The stock presents an opportunity for upside relative to the consensus target, but investors should monitor quarterly execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
